摘要
目的探讨雄激素受体(AR)蛋白表达及其基因获得/缺失改变与前列腺癌患者预后的关系。方法前列腺癌患者19例,年龄58～90岁,平均72岁,治疗前PSA为13.3～120 ng/mL,Gleason分级,其中高分化(Gleason评分(7分)2例,低分化(Gleason评分≥7分)17例。用免疫组化和FISH检测19例前列腺癌患者前列腺癌组织中的AR蛋白表达及其基因获得/缺失改变。结合临床资料分析其与前列腺癌预后的相关性。结果 19例患者标本中,发生AR基因获得2例,未发生AR基因获得17例,获得率为10.5%。其中2例发生AR基因获得标本均来自存活组,6例死亡组病例中均未发生AR基因获得。未复发组阳性强度显著高于死亡组(P<0.05)。结论前列腺癌患者AR蛋白表达中强阳性以及在治疗前出现AR基因获得可能提示预后良好。
Objective To study the clinical value of androgen receptor（AR） expression and its gene gain/lose in evaluating the prognosis of prostate cancer.Methods Nineteen patients aged 58～90 were examined,and their PSA level before therapy were 13.3～120 ng/mL.As for gleason score,two had high differentiation（gleason score7） and 17 had low differentiation（gleason score≥7）.Using immunohistochemical and FISH method,we analyzed the expression of AR and its gene gain/lose in PC tissues from the 19 samples.The correlation of AR expression and AR gene gain/lose with tumor prognosis in prostate cancer were analyzed in combination with the clinical data.Results Two of 19 were found AR gene gain,the positive rate was 10.5%.The two positive samples were both from the survival group.However,none of the 6 samples from the death group was found to be AR gene gain.AR positive intensity of the unrecurent group was significantly higher than that of the death group（P0.05）.Conclusion Strong positive AR expression in immunohistochemical test and AR gene gain occurring before therapy may be the indicators for favorable prognosis in prostate cancer.
出处
《基础医学与临床》
CSCD
北大核心
2010年第8期857-861,共5页
Basic and Clinical Medicine
